Efficacy of adalimumab in Behc, et's disease. Description of 6 cases

被引：17

作者：

Calvo Catala, Javier ^{[1
]}

Campos Fernandez, Cristina ^{[1
]}

Rueda Cid, Amalia ^{[1
]}

Gonzalez-Cruz Cervellera, Maria Isabel ^{[1
]}

Baixauli Rubio, Aurelio ^{[2
]}

Pastor Cubillo, Maria Dolores ^{[1
]}

机构：

[1] Consorcto Hosp Gen Univ, Serv Reumatol & Metab Oseo, Valencia, Spain

[2] Hosp Monises, Serv Med Interna, Valencia, Spain

来源：

REUMATOLOGIA CLINICA | 2011年 / 7卷 / 04期

关键词：

Behcet's disease; Uveitis; Adalimumab; Anti-TNF;

D O I：

10.1016/j.reuma.2010.10.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Behcet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab. (C) 2010 Elsevier Espana, S.L. All rights reserved.

引用

页码：258 / 261

页数：4

共 20 条

[1] Intestinal Behcet's Disease: Maintenance of Remission with Adalimumab Monotherapy [J].

Ariyachaipanich, Aekarach ;

Berkelhammer, Charles ;

Nicola, Haidy .

INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) :1769-1771

[2]

Belzunegui J, 2008, CLIN EXP RHEUMATOL, V26, pS133

[3] The role of biologic therapies in the management of systemic vasculitis [J].

Chan, A. T. ;

Flossmann, O. ;

Mukhtyar, C. ;

Jayne, D. R. W. ;

Luqmani, R. A. .

AUTOIMMUNITY REVIEWS, 2006, 5 (04) :273-278

[4]

Criteria for diagnosis of Behcet's disease, 1990, LANCET, V335, P1078, DOI DOI 10.1016/0140-6736(90)92643-V

[5] Current concepts in the etiology and treatment of Behcet disease [J].

Evereklioglu, C .

SURVEY OF OPHTHALMOLOGY, 2005, 50 (04) :297-350

[6] EULAR recommendations for the management of Behcet disease [J].

Hatemi, G. ;

Silman, A. ;

Bang, D. ;

Bodaghi, B. ;

Chamberlain, A. M. ;

Gul, A. ;

Houman, M. H. ;

Kotter, I. ;

Olivieri, I. ;

Salvarani, C. ;

Sfikakis, P. P. ;

Siva, A. ;

Stanford, M. R. ;

Stuebiger, N. ;

Yurdakul, S. ;

Yazici, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1656-1662

[7] Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease [J].

Hatemi, G. ;

Silman, A. ;

Bang, D. ;

Bodaghi, B. ;

Chamberlain, A. M. ;

Gul, A. ;

Houman, M. H. ;

Koetter, I. ;

Olivieri, I. ;

Salvarani, C. ;

Sfikakis, P. P. ;

Siva, A. ;

Stanford, M. R. ;

Stuebiger, N. ;

Yurdakul, S. ;

Yazici, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (10) :1528-1534

[8] The long-term mortality and morbidity of Behcet syndrome - A 2-decade outcome survey of 387 patients followed at a dedicated center [J].

Kural-Seyahi, E ;

Fresko, I ;

Seyahi, N ;

Ozyazgan, Y ;

Mat, C ;

Hamuryudan, V ;

Yurdakul, S ;

Yazici, H .

MEDICINE, 2003, 82 (01) :60-76

[9] Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report [J].

Lee, Sung-Won ;

Lee, Sang-Yeob ;

Kim, Ki-Nam ;

Jung, Jin-Kyu ;

Chung, Won-Tae .

CLINICAL RHEUMATOLOGY, 2010, 29 (01) :91-93

[10]

Callejas-Rubio JL, 2008, MED CLIN-BARCELONA, V131, P438

← 1 2 →